Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Deborah Arrindell"'
Autor:
Hamid R. Amouzadeh, Isaiah Dimery, Jonathan Werner, Gataree Ngarmchamnanrith, Michael J Engwall, Hugo M. Vargas, Deborah Arrindell
Publikováno v:
Translational Oncology, Vol 12, Iss 10, Pp 1296-1304 (2019)
Off-target activities of drug candidates observed during in vitro pharmacological profiling frequently do not translate to adverse events (AEs) in human. This could be because off-target activities do not have functional consequences, are not observe
Externí odkaz:
https://doaj.org/article/56cc11ab4f8a45ae841a6b7a14ff28a5
Autor:
Paul Nyirjesy, Robert S London, Christina A. Muzny, Oluwatosin Tosin Goje, Haywood L. Brown, Deborah Arrindell
Publikováno v:
Population health management. 24(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb394b19f9d6863f4efd70352a64727e
https://pubmed.ncbi.nlm.nih.gov/34590887
https://pubmed.ncbi.nlm.nih.gov/34590887
Autor:
Gataree Ngarmchamnanrith, Isaiah Dimery, Hamid R. Amouzadeh, Jonathan Werner, Michael J. Engwall, Hugo M. Vargas, Deborah Arrindell
Publikováno v:
Translational Oncology, Vol 12, Iss 10, Pp 1296-1304 (2019)
Translational Oncology
Translational Oncology
Off-target activities of drug candidates observed during in vitro pharmacological profiling frequently do not translate to adverse events (AEs) in human. This could be because off-target activities do not have functional consequences, are not observe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc64fa724ee119771739e4ffa14c566b
http://www.sciencedirect.com/science/article/pii/S1936523319300920
http://www.sciencedirect.com/science/article/pii/S1936523319300920
Autor:
Guiandre Joseph, Jessica Choudhry, Jacqueline Wright, Deborah Arrindell, Victoria M. Chia, William Kormany, Janet Franklin, Anthony S. Stein, Hamid R. Amouzadeh, Mandy Parson
Publikováno v:
Drug Safety
Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb44f7d52bc03c66c4f4b7fe8185437
https://doi.org/10.1007/s40264-018-0760-1
https://doi.org/10.1007/s40264-018-0760-1
Publikováno v:
The Journal of Urology. :1519
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01b95e14c9d3f94442f3b024eca5a8e1
https://doi.org/10.1097/00005392-199710000-00054
https://doi.org/10.1097/00005392-199710000-00054